NASDAQ:HOLX - Hologic Stock Price, Price Target & More

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Hologic, Inc. (NASDAQ:HOLX) released its quarterly earnings data on Wednesday, May, 2nd. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.53. The medical equipment provider had revenue of $789.30 million for the quarter, compared to analysts' expectations of $781.23 million. Hologic had a positive return on equity of 20.86% and a negative net margin of 4.15%. The firm's quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.50 EPS. View Hologic's Earnings History.

Hologic issued an update on its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $2.22-2.27 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.26. The company issued revenue guidance of $3.18-3.21 billion, compared to the consensus revenue estimate of $3.25 billion.Hologic also updated its Q3 guidance to $0.55-0.57 EPS.

14 brokerages have issued 1-year target prices for Hologic's stock. Their predictions range from $39.00 to $52.00. On average, they expect Hologic's stock price to reach $45.00 in the next twelve months. This suggests a possible upside of 9.4% from the stock's current price. View Analyst Ratings for Hologic.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Hologic saw a drop in short interest in June. As of June 15th, there was short interest totalling 8,793,455 shares, a drop of 19.1% from the May 31st total of 10,875,616 shares. Based on an average daily trading volume, of 2,507,848 shares, the days-to-cover ratio is currently 3.5 days. Currently, 3.2% of the company's stock are sold short. View Hologic's Current Options Chain.

Some companies that are related to Hologic include FRESENIUS SE &/S (FSNUY), Humana (HUM), Express Scripts (ESRX), Zoetis (ZTS), BEXIMCO PHARMAC/S GDR REGS (BXP), Baxter International (BAX), Regeneron Pharmaceuticals (REGN), HCA Healthcare (HCA), Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Edwards Lifesciences (EW), ESSILOR Intl S/S (ESLOY), Fresenius Medical Care AG & Co. (FMS), Alexion Pharmaceuticals (ALXN) and Actelion (ALIOF).

News headlines about HOLX stock have trended somewhat positive this week, according to Accern. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Hologic earned a media sentiment score of 0.07 on Accern's scale. They also gave media coverage about the medical equipment provider an impact score of 45.36 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Hologic's stock is owned by many different of institutional and retail investors. Top institutional shareholders include American Capital Management Inc. (0.43%), Davis R M Inc. (0.27%), Gateway Investment Advisers LLC (0.14%), Bank of Montreal Can (0.10%), Retirement Systems of Alabama (0.05%) and Thompson Investment Management Inc. (0.03%). Company insiders that own Hologic stock include Allison P Bebo, Charles J Dockendorff, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Namal Nawana, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

HOLX stock was sold by a variety of institutional investors in the last quarter, including Davis R M Inc., Municipal Employees Retirement System of Michigan, Hartford Investment Management Co., Central Bank & Trust Co., Jackson Financial Management, Retirement Systems of Alabama, Amalgamated Bank and Webster Bank N. A.. Company insiders that have sold Hologic company stock in the last year include Allison P Bebo, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy and Peter J Valenti III. View Insider Buying and Selling for Hologic.

HOLX stock was purchased by a variety of institutional investors in the last quarter, including Gateway Investment Advisers LLC, Bank of Montreal Can, Nisa Investment Advisors LLC, Reilly Financial Advisors LLC, DnB Asset Management AS, Curbstone Financial Management Corp, Eastern Bank and Ledyard National Bank. Company insiders that have bought Hologic stock in the last two years include Charles J Dockendorff and Namal Nawana. View Insider Buying and Selling for Hologic.

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HOLX stock can currently be purchased for approximately $41.12.

Hologic has a market capitalization of $11.28 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.03 on an earnings per share basis. Hologic employs 6,233 workers across the globe.

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]